Drug-eluting stent thrombosis in routine clinical practice two-year outcomes and predictors from the Taxus arrive registries

Circulation: Cardiovascular Interventions

Volumn 2, Issue 4, 2009, Pages 285-293

  Lasala, John M ^a   Cox, David A ^b   Dobies, David ^c   Baran, Kenneth ^d   Bachinsky, William B ^e   Rogers, Edwin W ^f   Breall, Jeffrey A ^g   Lewis, David H ^h   Song, Aijun ⁱ   Starzyk, Ruth M ⁱ   Mascioli, Stephen R ⁱ   Dawkins, Keith D ⁱ   Baim, Donald S ⁱ  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LEHIGH VALLEY HOSPITAL   (United States)

^c GENESYS REGIONAL MEDICAL CENTER   (United States)

^d St Paul Heart Clinic   (United States)

^e Pinnacle Health System   (United States)

^f Cardiology Consultants   (United States)

^g INDIANA UNIVERSITY   (United States)

^h Heart Vascular Institute   (United States)

ⁱ BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Angioplasty; Coronary disease; Registries; Stents; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ARTICLE; BRACHYTHERAPY; CALCIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; DRUG ELUTING STENT; DRUG WITHDRAWAL; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; VASCULAR LESION;

EID: 77949429063     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.109.852178.109.852178     Document Type: Article

References (40)

1. Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, Popma JJ, Serruys PW, Kimura T, Williams DO, Windecker S, Krucoff MW. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007;50:109-118.
2. Windecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116:1952-1965.
3. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol. 2007;50:119-127.
4. Farb A, Boam AB. Stent thrombosis redux-the FDA perspective. N Engl J Med. 2007;356:984-987.
5. Lasala JM, Cox DA, Dobies D, Muhlestein JB, Katopodis JN, Revtyak G, Baim DS. Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry. Catheter Cardiovasc Interv. 2008;72:433-445.
6. Lasala JM, Cox DA, Lewis SL, Tadros PN, Haas RC, Schweiger MJ, Chhabra A, Untereker WJ, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS. Expanded use of the TAXUS Express stent: 2-year insights on safety from the 7500-patient ARRIVE registry program. EuroIntervention. 2009;5:67-77.
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351.
9. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
10. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-1671.
11. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092.
12. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008. (Pubitemid 46376800)
13. Allocco DJ, Dawkins KD, Baim DS, Leon MB. The impact of nonstent related progression of underlying coronary artery disease on late clinical outcomes after paclitaxel-eluting stents [TCT Abstract 346]. Am J Cardiol. 2008;102:137i-138i.
14. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
15. Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Smith H, Edmunds J, Varanasi J, Simonton CA, Group S. Outcomes and complications with off-label use of drug-eluting stents. Results from the STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Coll Cardiol Interv. 2008;1:405-414.
16. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001-2009.
17. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992-2000.
18. Pinto Slottow TL, Steinberg DH, Roy PK, Buch AN, Okabe T, Xue Z, Kaneshige K, Torguson R, Lindsay J, Pichard AD, Satler LF, Suddath WO, Kent KM, Waksman R. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol. 2008;102:298-303.
19. Mishkel GJ, Moore AL, Markwell S, Shelton ME. Correlates of late and very late thrombosis of drug eluting stents. Am Heart J. 2008;156:141-147.
20. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-678.
21. Yan BP, Duffy SJ, Clark DJ, Lefkovits J, Warren R, Gurvitch R, Lew R, Sebastian M, Brennan A, Andrianopoulos N, Reid CM, Ajani AE. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am J Cardiol. 2008;101:1716-1722.
22. Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamaki K, Junker A, Aaroe J, Abildgaard U, Ravkilde J, Engstrom T, Jensen JS, Andersen HR, Botker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrom SZ, Stephansen GB, Lassen JF. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008;299:409-416.
23. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116: 745-754.
24. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006;113:1434-1441.
25. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-1140.
26. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Mockel M, Ochala A, Kellock A, Parise H, Mehran R. The HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-1959.
27. van Werkum JW, Heestermans AA, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, Zwart B, Brueren BR, Koolen JJ, Dambrink JH, van't Hof AW, Verheugt FW, ten Berg JM. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009;119:828-834.
28. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003;108:2-5.
29. Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2009;119:687-698.
30. Baran KW, Lasala JM, Cox DA, Song A, Deshpande MC, Jacoski MV, Mascioli SR. ARRIVE Participating Physicians. A clinical risk score for prediction of stent thrombosis. Am J Cardiol. 2008;102:541-545.
31. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734-739. (Pubitemid 46210116)
32. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261-295.
33. Paradis JM, Ducrocq G, Tanguay JF. Antiplatelet therapy following drug-eluting stent implantation: new clinical data and recommendations. Minerva Cardioangiol. 2008;56:139-154.
34. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
35. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352-356.
36. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005;46:1827-1832.
37. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl M-L. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel. The PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Interv. 2008;1:612-619.
38. Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet J-P, Montalescot G, Cazenave J-P, Dickele M-C, Monassier J-P, Gachet C. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention. Results from the VASP-02 (vasodilator-stimulated phosphoprotein-02) randomized study. J Am Coll Cardiol Interv. 2008;1:631-638.
39. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- thrombolysis in myocardial infarction 38. Circulation. 2008;118:1626-1636.
40. Mauri L. Dual anti-platelet therapy (DAPT) randomized trial. Presented at the Transcatheter Cardiovascular Therapeutics Symposium, October 12-17, 2008, Washington, DC. Available at: http://www.hcri.harvard.edu/uploads/news-event- documents/dapt-design-slides-tct. Accessed November 6, 2008.